Overview Dividends

(MRUS) Merus BV - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0011606264

Bispecific,Antibodies,Cancer,Clinical,Pipeline

MRUS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 74.11%
EPS Trend (3Y Correlation): 9.1%

MRUS Revenue

Revenue Growth (3Y CAGR): 4.07%
Revenue Trend (3Y Correlation): 22.3%

Description: MRUS Merus BV July 28, 2025

Merus BV is a clinical-stage immuno-oncology company developing innovative antibody therapeutics, focusing on bispecific antibodies to treat various cancers, including pancreatic adenocarcinoma, non-small cell lung cancer, and solid tumors. The companys pipeline includes several promising candidates, such as BIZENGRI, MCLA-158, and MCLA-129, targeting specific cancer types.

From a business perspective, Merus has established strategic collaborations with pharmaceutical giants like Eli Lilly, Ono Pharmaceutical, and Betta Pharmaceuticals, potentially validating its technology and providing future revenue streams. With a market capitalization of approximately $4.575 billion USD, Merus has a significant presence in the biotechnology sector.

To further analyze Merus performance, we can examine key performance indicators (KPIs) such as cash burn rate, research and development (R&D) expenses, and pipeline progression. A high cash burn rate could be a concern, given the companys negative return on equity (RoE) of -41.18%. However, the progress of its clinical trials and the potential for future collaborations or partnerships could offset this concern. Additionally, the companys ability to advance its pipeline and achieve regulatory milestones will be crucial in driving future growth.

Merus stock price has shown significant growth, with a 52-week high of $66.82 and a low of $34.89, indicating a potential increase in investor interest. To make an informed investment decision, its essential to monitor the companys progress in its clinical trials, as well as any updates on its collaborations and partnerships.

MRUS Stock Overview

Market Cap in USD	7,190m
Sub-Industry	Biotechnology
IPO / Inception	2016-05-19

MRUS Stock Ratings

Growth Rating	87.3%
Fundamental	33.4%
Dividend Rating	-
Return 12m vs S&P 500	52.8%
Analyst Rating	4.76 of 5

MRUS Dividends

Currently no dividends paid

MRUS Growth Ratios

Growth Correlation 3m	93%
Growth Correlation 12m	76.4%
Growth Correlation 5y	72.2%
CAGR 5y	78.08%
CAGR/Max DD 3y (Calmar Ratio)	1.86
CAGR/Mean DD 3y (Pain Ratio)	5.83
Sharpe Ratio 12m	-0.14
Alpha	60.26
Beta	1.261
Volatility	43.12%
Current Volume	1084.9k
Average Volume 20d	2414.5k
Stop Loss	92 (-3%)
Signal	0.55

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-344.1m TTM) > 0 and > 6% of Revenue (6% = 3.10m TTM)

FCFTA -0.32 (>2.0%) and ΔFCFTA -20.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1309 % (prev 2220 %; Δ -910.9pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.32 (>3.0%) and CFO -312.8m > Net Income -344.1m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (71.1m) change vs 12m ago 14.95% (target <= -2.0% for YES)

Gross Margin -210.0% (prev -165.8%; Δ -44.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 5.52% (prev 3.66%; Δ 1.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -10.30 (EBITDA TTM -315.0m / Interest Expense TTM 30.8m) >= 6 (WARN >= 3)

Altman Z'' -10.90

(A) 0.69 = (Total Current Assets 768.3m - Total Current Liabilities 91.6m) / Total Assets 980.2m

(B) -1.25 = Retained Earnings (Balance) -1.22b / Total Assets 980.2m

warn (B) unusual magnitude: -1.25 — check mapping/units

(D) -8.65 = Book Value of Equity -1.20b / Total Liabilities 138.4m

Total Rating: -10.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.40

1. Piotroski 0.0pt = -5.0

2. FCF Yield -4.83% = -2.41

3. FCF Margin data missing

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda 1.37 = 1.19

6. ROIC - WACC (= -56.68)% = -12.50

7. RoE -49.36% = -2.50

8. Rev. Trend 22.34% = 1.68

9. EPS Trend 9.12% = 0.46

What is the price of MRUS shares?

As of November 03, 2025, the stock is trading at USD 94.86 with a total of 1,084,925 shares traded.
Over the past week, the price has changed by +0.27%, over one month by +0.75%, over three months by +41.73% and over the past year by +85.16%.

Is Merus BV a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Merus BV (NASDAQ:MRUS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 33.40 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRUS is around 132.48 USD . This means that MRUS is currently undervalued and has a potential upside of +39.66% (Margin of Safety).

Is MRUS a buy, sell or hold?

Merus BV has received a consensus analysts rating of 4.76. Therefore, it is recommended to buy MRUS.

Strong Buy: 13
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MRUS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	97	2.3%
Analysts Target Price	97	2.3%
ValueRay Target Price	150.6	58.7%

MRUS Fundamental Data Overview October 27, 2025

Market Cap USD = 7.19b (7.19b USD * 1.0 USD.USD)
P/S = 127.8798
P/B = 8.4767
Beta = 1.261
Revenue TTM = 51.7m USD
EBIT TTM = -317.2m USD
EBITDA TTM = -315.0m USD
Long Term Debt = 11.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.25m USD (from shortTermDebt, last quarter)
Debt = 11.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -431.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.49b USD (7.19b + Debt 11.0m - CCE 710.2m)
Interest Coverage Ratio = -10.30 (Ebit TTM -317.2m / Interest Expense TTM 30.8m)
FCF Yield = -4.83% (FCF TTM -313.3m / Enterprise Value 6.49b)
FCF Margin = -606.2% (FCF TTM -313.3m / Revenue TTM 51.7m)
Net Margin = -665.8% (Net Income TTM -344.1m / Revenue TTM 51.7m)
Gross Margin = -210.0% ((Revenue TTM 51.7m - Cost of Revenue TTM 160.2m) / Revenue TTM)
Gross Margin QoQ = -964.0% (prev -202.5%)
Tobins Q-Ratio = 6.62 (Enterprise Value 6.49b / Total Assets 980.2m)
Interest Expense / Debt = 279.9% (Interest Expense 30.8m / Debt 11.0m)
Taxrate = -1.20% (negative due to tax credits) (1.59m / -132.7m)
NOPAT = -321.0m (EBIT -317.2m * (1 - -1.20%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 8.39 (Total Current Assets 768.3m / Total Current Liabilities 91.6m)
Debt / Equity = 0.01 (Debt 11.0m / totalStockholderEquity, last quarter 841.7m)
Debt / EBITDA = 1.37 (negative EBITDA) (Net Debt -431.8m / EBITDA -315.0m)
Debt / FCF = 1.38 (negative FCF - burning cash) (Net Debt -431.8m / FCF TTM -313.3m)
Total Stockholder Equity = 697.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.11% (Net Income -344.1m / Total Assets 980.2m)
RoE = -49.36% (Net Income TTM -344.1m / Total Stockholder Equity 697.3m)
RoCE = -44.79% (EBIT -317.2m / Capital Employed (Equity 697.3m + L.T.Debt 11.0m))
RoIC = -46.04% (negative operating profit) (NOPAT -321.0m / Invested Capital 697.3m)
WACC = 10.64% (E(7.19b)/V(7.20b) * Re(10.66%) + (debt cost/tax rate unavailable))
Discount Rate = 10.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.88%
Fair Price DCF = unknown (Cash Flow -313.3m)
EPS Correlation: 9.12 | EPS CAGR: 74.11% | SUE: 2.67 | # QB: 1
Revenue Correlation: 22.34 | Revenue CAGR: 4.07% | SUE: -0.31 | # QB: 0

Additional Sources for MRUS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle